Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
Aclaris Therapeutics和其他一隻低於5美元的股票內部人士正在購買
The Dow Jones index closed higher by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週五收高約0.2％。當內部人士買入或賣出股票時，這表示他們對公司前景的信心或擔憂。有興趣購買低價股票的投資者和交易者可以將此視爲他們整體投資或交易決策的因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是幾個近期關於低價股的值得關注的內部交易。了解更多，請查看Benzinga內幕交易平台。
Aclaris Therapeutics
aclaris therapeutics
- The Trade: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) 10% owner Braden Michael Leonard bought a total of 352,397 shares at an average price of $1.15. To acquire these shares, it cost around $405,894.
- What's Happening: On May 7, Aclaris Therapeutics posted upbeat quarterly results.
- What Aclaris Therapeutics Does: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States.
- 交易：Aclaris Therapeutics，Inc。（納斯達克：ACRS）的大股東Braden Michael Leonard以平均價1.15美元買入了共計352，397股。購買這些股票需要花費約405,894美元。
- 最新情況：5月7日，aclaris therapeutics發佈了樂觀的季度業績。
- aclaris therapeutics inc是一家在美國運營的臨床階段生物製藥公司。
RENN Fund
renn fund
- The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 184 shares at an average price of $1.74. To acquire these shares, it cost around $320.
- What's Happening: RENN Fund shares rose around 5% over the past month.
- What RENN Fund Does: RENN Fund Inc is active in the financial services domain.
- 交易：RENN Fund，Inc。（紐交所：RCG）總裁兼首席執行官Murray Stahl以平均價1.74美元買入了共計184股。購買這些股票需要花費約320美元。
- 最近一個月REN Fund股票上漲約5％。
- RENN Fund Inc在金融服務領域活躍。